X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-08-28 | VIRX | Chevallard Daniel R. | CFO, COO | S - Sale+OE | $1.45 | -3,512 | 95,653 | -4% | -$5,092 | |||||
| D | 2023-05-25 | VIRX | Chevallard Daniel R. | CFO, COO | S - Sale+OE | $1.42 | -3,635 | 92,277 | -4% | -$5,160 | |||||
| D | 2023-02-27 | VIRX | Rojkjaer Lisa | Chief Medical Officer | S - Sale+OE | $1.68 | -2,156 | 48,087 | -4% | -$3,625 | |||||
| D | 2023-02-27 | VIRX | Chevallard Daniel R. | CFO, COO | S - Sale+OE | $1.68 | -3,599 | 89,023 | -4% | -$6,051 | |||||
| D | 2022-11-28 | VIRX | Chevallard Daniel R. | CFO, COO | S - Sale+OE | $2.72 | -3,532 | 85,733 | -4% | -$9,606 | |||||
| D | 2022-11-28 | VIRX | Rojkjaer Lisa | Chief Medical Officer | S - Sale+OE | $2.72 | -2,116 | 46,116 | -4% | -$5,754 | |||||
| D | 2022-08-26 | VIRX | Rojkjaer Lisa | Chief Medical Officer | S - Sale+OE | $4.01 | -2,190 | 44,105 | -5% | -$8,786 | |||||
| D | 2022-08-26 | VIRX | Chevallard Daniel R. | CFO, COO | S - Sale+OE | $4.02 | -3,655 | 82,376 | -4% | -$14,679 | |||||
| D | 2022-08-26 | VIRX | Royston Ivor | CEO, Pres | S - Sale+OE | $4.01 | -13,379 | 631,369 | -2% | -$53,656 | |||||
| D | 2022-05-26 | VIRX | Royston Ivor | CEO, Pres | S - Sale+OE | $1.90 | -13,162 | 619,529 | -2% | -$25,022 | |||||
| D | 2022-05-26 | VIRX | Rojkjaer Lisa | Chief Medical Officer | S - Sale+OE | $1.90 | -2,154 | 42,168 | -5% | -$4,095 | |||||
| D | 2022-05-26 | VIRX | Chevallard Daniel R. | CFO, COO | S - Sale+OE | $1.90 | -3,596 | 79,142 | -4% | -$6,836 | |||||
| D | 2022-02-28 | VIRX | Royston Ivor | CEO, Pres | S - Sale+OE | $2.78 | -14,635 | 607,472 | -2% | -$40,678 | |||||
| D | 2022-02-28 | VIRX | Rojkjaer Lisa | Chief Medical Officer | S - Sale+OE | $2.78 | -2,395 | 40,195 | -6% | -$6,657 | |||||
| D | 2022-02-28 | VIRX | Chevallard Daniel R. | CFO, COO | S - Sale+OE | $2.78 | -3,998 | 75,849 | -5% | -$11,112 | |||||
| DM | 2021-11-26 | VIRX | Rojkjaer Lisa | Chief Medical Officer | S - Sale+OE | $4.81 | -4,541 | 38,463 | -11% | -$21,847 | |||||
| DM | 2021-11-26 | VIRX | Chevallard Daniel R. | CFO, COO | S - Sale+OE | $4.81 | -7,579 | 72,958 | -9% | -$36,464 | |||||
| DM | 2021-11-26 | VIRX | Royston Ivor | CEO, Pres | S - Sale+OE | $4.81 | -27,747 | 589,888 | -4% | -$133,495 | |||||
2021-11-15 | VIRX | Royston Ivor | CEO, Pres | P - Purchase | $5.56 | +8,000 | 567,198 | +1% | +$44,480 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |